Good points. I do not see the Alpha Sigma RFR as being a negative.. If we get an offer from a big pharma they will be on notice that a low offer could be unsuccessful due to the RFR; it should encourage the "best offer possible" and set the negotiations on a higher level.

I believe the silence this week is due to LW and IPIX reviewing interest and offers.UC and possibly Crohn's disease are huge markets and Brilacidin has the potential to be a dominating, very profitable treatment.

Time will tell

Good luck,Farrell